{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:33Z","timestamp":1787020833612,"version":"build-2736575974"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014261","name":"National Institute for Health Care Management Foundation","doi-asserted-by":"publisher","award":["R01AI130186"],"award-info":[{"award-number":["R01AI130186"]}],"id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014261","name":"National Institute for Health Care Management Foundation","doi-asserted-by":"publisher","award":["R01AI130186"],"award-info":[{"award-number":["R01AI130186"]}],"id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014261","name":"National Institute for Health Care Management Foundation","doi-asserted-by":"publisher","award":["R01AI130186"],"award-info":[{"award-number":["R01AI130186"]}],"id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"DOI":"10.1186\/s13099-026-00842-4","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:39:11Z","timestamp":1781501951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Carbadox, a veterinary growth promoter exhibits anticlostridial activity through induction of oxidative stress in Clostridioides difficile"],"prefix":"10.1186","volume":"18","author":[{"given":"Ahmed A.","family":"Abouelkhair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader S.","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton C.","family":"Caswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","unstructured":"Lev V et al. Health care-associated Clostridioides difficile infection: Learning the perspectives of health care workers to build successful strategies. Am J Infect Control, 2023. 52(3), 284\u2013292. https:\/\/doi.org\/10.1016\/j.ajic.2023.08.008","DOI":"10.1016\/j.ajic.2023.08.008"},{"issue":"1","key":"842_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","volume":"23","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132.","journal-title":"BMC Infect Dis"},{"key":"842_CR3","unstructured":"CDC. CDC\u2019s 2022 Antibiotic Resistance Threats Report. 2022."},{"issue":"1","key":"842_CR4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41467-021-21355-5","volume":"12","author":"P Castro-C\u00f3rdova","year":"2021","unstructured":"Castro-C\u00f3rdova P, et al. Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection. Nat Commun. 2021;12(1):1140.","journal-title":"Nat Commun"},{"issue":"3","key":"842_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/1040841X.2022.2072705","volume":"49","author":"R Pal","year":"2023","unstructured":"Pal R, et al. Probiotics: insights and new opportunities for Clostridioides difficile intervention. Crit Rev Microbiol. 2023;49(3):414\u201334.","journal-title":"Crit Rev Microbiol"},{"key":"842_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jgar.2019.10.005","volume":"21","author":"D Mody","year":"2020","unstructured":"Mody D, Athamneh AIM, Seleem MN. Curcumin: A natural derivative with antibacterial activity against Clostridium difficile. J Glob Antimicrob Resist. 2020;21:154\u201361.","journal-title":"J Glob Antimicrob Resist"},{"issue":"7883","key":"842_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-021-03986-2","volume":"599","author":"L Maier","year":"2021","unstructured":"Maier L, et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature. 2021;599(7883):120\u20134.","journal-title":"Nature"},{"issue":"12","key":"842_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41579-023-00936-9","volume":"21","author":"L de Nies","year":"2023","unstructured":"de Nies L, Kobras CM, Stracy M. Antibiotic-induced collateral damage to the microbiota and associated infections. Nat Rev Microbiol. 2023;21(12):789\u2013804.","journal-title":"Nat Rev Microbiol"},{"key":"842_CR9","doi-asserted-by":"publisher","first-page":"175628482199473","DOI":"10.1177\/1756284821994736","volume":"14","author":"K Sehgal","year":"2021","unstructured":"Sehgal K, Khanna S. Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. Therapeutic Adv Gastroenterol. 2021;14:1756284821994736.","journal-title":"Therapeutic Adv Gastroenterol"},{"issue":"7903","key":"842_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","volume":"603","author":"D Paik","year":"2022","unstructured":"Paik D, et al. Human gut bacteria produce \u03a4\u039717-modulating bile acid metabolites. Nature. 2022;603(7903):907\u201312.","journal-title":"Nature"},{"issue":"5","key":"842_CR11","first-page":"e39029","volume":"15","author":"A Rafey","year":"2023","unstructured":"Rafey A, et al. Antibiotics Associated With Clostridium difficile Infection. Cureus. 2023;15(5):e39029.","journal-title":"Cureus"},{"issue":"1","key":"842_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41467-020-20746-4","volume":"12","author":"JR Fletcher","year":"2021","unstructured":"Fletcher JR, et al. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. Nat Commun. 2021;12(1):462.","journal-title":"Nat Commun"},{"issue":"1","key":"842_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/gmic.26854","volume":"5","author":"DN Gerding","year":"2014","unstructured":"Gerding DN, et al. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes. 2014;5(1):15\u201327.","journal-title":"Gut Microbes"},{"issue":"Pt 2","key":"842_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1099\/jmm.0.45804-0","volume":"54","author":"F Barbut","year":"2005","unstructured":"Barbut F, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54(Pt 2):181\u20135.","journal-title":"J Med Microbiol"},{"issue":"6","key":"842_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3201\/eid\/1706.101483","volume":"17","author":"S Bacci","year":"2011","unstructured":"Bacci S, et al. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis. 2011;17(6):976\u201382.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"842_CR16","doi-asserted-by":"publisher","first-page":"1884516","DOI":"10.1080\/19490976.2021.1884516","volume":"13","author":"S L\u00f3pez-C\u00e1rdenas","year":"2021","unstructured":"L\u00f3pez-C\u00e1rdenas S, et al. The prognostic value of toxin B and binary toxin in Clostridioides difficile infection. Gut Microbes. 2021;13(1):1884516.","journal-title":"Gut Microbes"},{"key":"842_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14050305","author":"A Mart\u00ednez-Mel\u00e9ndez","year":"2022","unstructured":"Mart\u00ednez-Mel\u00e9ndez A, et al. An update on Clostridioides difficile binary toxin. Toxins (Basel). 2022.14(5), 305. https:\/\/doi.org\/10.3390\/toxins14050305","journal-title":"Toxins (Basel)"},{"issue":"7","key":"842_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1\u201348.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"842_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nrgastro.2015.220","volume":"13","author":"LK Kociolek","year":"2016","unstructured":"Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Reviews Gastroenterol Hepatol. 2016;13(3):150\u201360.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"1","key":"842_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5009\/gnl18071","volume":"13","author":"JH Song","year":"2019","unstructured":"Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver. 2019;13(1):16\u201324.","journal-title":"Gut Liver"},{"issue":"1","key":"842_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","volume":"40","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"842_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/cid\/ciaf028","volume":"80","author":"SN Redmond","year":"2025","unstructured":"Redmond SN, et al. Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital. Clin Infect Dis. 2025;80(5):984\u201391.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"842_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cid\/ciae087","volume":"79","author":"TA Eubank","year":"2024","unstructured":"Eubank TA, et al. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024;79(1):15\u201321.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"842_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/19490976.2017.1286006","volume":"8","author":"MH Woodworth","year":"2017","unstructured":"Woodworth MH, et al. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes. 2017;8(3):225\u201337.","journal-title":"Gut Microbes"},{"issue":"9","key":"842_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s12276-020-0437-6","volume":"52","author":"M Cordaillat-Simmons","year":"2020","unstructured":"Cordaillat-Simmons M, Rouanet A, Pot B. Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med. 2020;52(9):1397\u2013406.","journal-title":"Exp Mol Med"},{"key":"842_CR26","doi-asserted-by":"crossref","unstructured":"Sexton J. Repurposing generic drugs can reduce time and cost to develop new treatments \u2013 but low profitability remains a barrier. 2022.","DOI":"10.64628\/AAI.dftakmwj7"},{"issue":"1","key":"842_CR27","doi-asserted-by":"publisher","first-page":"7701","DOI":"10.1038\/s41598-020-64882-9","volume":"10","author":"NS Abutaleb","year":"2020","unstructured":"Abutaleb NS, Seleem MN. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci Rep. 2020;10(1):7701.","journal-title":"Sci Rep"},{"issue":"5","key":"842_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ja.2017.11","volume":"70","author":"A Crump","year":"2017","unstructured":"Crump A. Ivermectin: enigmatic multifaceted \u2018wonder\u2019 drug continues to surprise and exceed expectations. J Antibiot. 2017;70(5):495\u2013505.","journal-title":"J Antibiot"},{"issue":"6","key":"842_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.anaerobe.2005.04.005","volume":"11","author":"DM Citron","year":"2005","unstructured":"Citron DM, et al. In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia and Bacteroides fragilis. Anaerobe. 2005;11(6):315\u20137.","journal-title":"Anaerobe"},{"issue":"6","key":"842_CR30","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciad792","volume":"78","author":"PC Okhuysen","year":"2024","unstructured":"Okhuysen PC, et al. Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024;78(6):1462\u201372.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"842_CR31","doi-asserted-by":"publisher","first-page":"e00273","DOI":"10.1128\/msphere.00273-24","volume":"9","author":"AA Abouelkhair","year":"2024","unstructured":"Abouelkhair AA, Seleem MN. Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile. mSphere. 2024;9(7):e00273\u201324.","journal-title":"mSphere"},{"key":"842_CR32","unstructured":"P. Constable, K.W. Hinchcliff, S. Done and W. Gruenberg Practical Antimicrobial Therapeutics. Veterinary Medicine (Eleventh Edition). W.B. Saunders; 2017. pp. 153\u201374."},{"issue":"1","key":"842_CR33","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1038\/s41598-021-84759-9","volume":"11","author":"J Muurinen","year":"2021","unstructured":"Muurinen J, et al. Swine growth promotion with antibiotics or alternatives can increase antibiotic resistance gene mobility potential. Sci Rep. 2021;11(1):5485.","journal-title":"Sci Rep"},{"issue":"8","key":"842_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/antibiotics9080463","volume":"9","author":"Y-T Hung","year":"2020","unstructured":"Hung Y-T, et al. Analysis of Gastrointestinal Responses Revealed Both Shared and Specific Targets of Zinc Oxide and Carbadox in Weaned Pigs. Antibiotics. 2020;9(8):463.","journal-title":"Antibiotics"},{"key":"842_CR35","doi-asserted-by":"publisher","first-page":"p1948","DOI":"10.3389\/fmicb.2016.01948","volume":"7","author":"F Xu","year":"2016","unstructured":"Xu F, et al. Mechanisms of Antibacterial Action of Quinoxaline 1,4-di-N-oxides against Clostridium perfringens and Brachyspira hyodysenteriae. Front Microbiol. 2016;7:p1948.","journal-title":"Front Microbiol"},{"issue":"2","key":"842_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/03602532.2016.1189560","volume":"48","author":"X Wang","year":"2016","unstructured":"Wang X, et al. The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016;48(2):159\u201382.","journal-title":"Drug Metab Rev"},{"issue":"8","key":"842_CR37","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1128\/JCM.00834-16","volume":"54","author":"S Mirajkar Nandita","year":"2016","unstructured":"Mirajkar Nandita S, Davies Peter R, Gebhart Connie J. Antimicrobial Susceptibility Patterns of Brachyspira Species Isolated from Swine Herds in the United States. J Clin Microbiol. 2016;54(8):2109\u201319.","journal-title":"J Clin Microbiol"},{"key":"842_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fphar.2018.00361","volume":"9","author":"Q Liu","year":"2018","unstructured":"Liu Q, et al. Mequindox Induced Genotoxicity and Carcinogenicity in Mice. Front Pharmacol. 2018;9:361.","journal-title":"Front Pharmacol"},{"key":"842_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01490-17","author":"LB Price","year":"2017","unstructured":"Price LB. Bacterial whack-a-mole: reconsidering the public health relevance of using Carbadox in food animals. mBio. 2017. 8(5), e01490-17. https:\/\/doi.org\/10.1128\/mBio.01490-17","journal-title":"mBio"},{"key":"842_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02115-19","author":"NS Abutaleb","year":"2020","unstructured":"Abutaleb NS, Seleem MN. Repurposing the antiamoebic drug Diiodohydroxyquinoline for treatment of Clostridioides difficile infections. Antimicrob Agents Chemother. 2020. .64(6), e02115-19. https:\/\/doi.org\/10.1128\/AAC.02115-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"842_CR41","doi-asserted-by":"publisher","first-page":"e0309624","DOI":"10.1371\/journal.pone.0309624","volume":"19","author":"BJ Stolz","year":"2024","unstructured":"Stolz BJ, Abouelkhair AA, Seleem MN. Screening novel antiviral compounds to treat Clostridioides difficile infections. PLoS ONE. 2024;19(12):e0309624.","journal-title":"PLoS ONE"},{"issue":"21","key":"842_CR42","doi-asserted-by":"publisher","first-page":"p9772","DOI":"10.1021\/acs.jmedchem.9b01198","volume":"62","author":"X Shao","year":"2019","unstructured":"Shao X, et al. Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors. J Med Chem. 2019;62(21):p9772\u20139791.","journal-title":"J Med Chem"},{"issue":"2","key":"842_CR43","doi-asserted-by":"publisher","first-page":"e0341857","DOI":"10.1371\/journal.pone.0341857","volume":"21","author":"BJ Stolz","year":"2026","unstructured":"Stolz BJ, et al. Evaluation of the antibacterial activity of the natural product \u03b1-mangostin against Clostridioides difficile. PLoS ONE. 2026;21(2):e0341857.","journal-title":"PLoS ONE"},{"issue":"9","key":"842_CR44","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1128\/AAC.00104-11","volume":"55","author":"F Babakhani","year":"2011","unstructured":"Babakhani F, et al. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother. 2011;55(9):4427\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"842_CR45","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1038\/s41598-020-64352-2","volume":"10","author":"H Mohammad","year":"2020","unstructured":"Mohammad H, Abutaleb NS, Seleem MN. Auranofin Rapidly Eradicates Methicillin-resistant Staphylococcus aureus (MRSA) in an Infected Pressure Ulcer Mouse Model. Sci Rep. 2020;10(1):7251.","journal-title":"Sci Rep"},{"key":"842_CR46","doi-asserted-by":"crossref","unstructured":"Abouelkhair AA, Abutaleb NS, Seleem MN. The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile. Int J Antimicrob Agents, 2025: 67 (1): p.107649.","DOI":"10.1016\/j.ijantimicag.2025.107649"},{"key":"842_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4939-6361-4_9","volume":"1476","author":"AN Edwards","year":"2016","unstructured":"Edwards AN, McBride SM. Isolating and Purifying Clostridium difficile Spores. Methods Mol Biol. 2016;1476:117\u201328.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"842_CR48","doi-asserted-by":"publisher","first-page":"e0161200","DOI":"10.1371\/journal.pone.0161200","volume":"11","author":"CH Chilton","year":"2016","unstructured":"Chilton CH, et al. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. PLoS ONE. 2016;11(8):e0161200.","journal-title":"PLoS ONE"},{"issue":"1","key":"842_CR49","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1128\/AAC.01611-12","volume":"57","author":"CA Allen","year":"2013","unstructured":"Allen CA, et al. Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores. Antimicrob Agents Chemother. 2013;57(1):664\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"842_CR50","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1021\/acs.jmedchem.0c01198","volume":"63","author":"GA Naclerio","year":"2020","unstructured":"Naclerio GA, et al. Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo. J Med Chem. 2020;63(20):11934\u201344.","journal-title":"J Med Chem"},{"issue":"3","key":"842_CR51","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1128\/AAC.00688-10","volume":"55","author":"DJ Farrell","year":"2011","unstructured":"Farrell DJ, et al. In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler\u2019s diarrhea and Clostridium difficile. Antimicrob Agents Chemother. 2011;55(3):992\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"842_CR52","doi-asserted-by":"publisher","first-page":"e0267859","DOI":"10.1371\/journal.pone.0267859","volume":"17","author":"R Pal","year":"2022","unstructured":"Pal R, Seleem MN. Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo. PLoS ONE. 2022;17(8):e0267859.","journal-title":"PLoS ONE"},{"issue":"2","key":"842_CR53","doi-asserted-by":"publisher","first-page":"e70269","DOI":"10.1002\/mbo3.70269","volume":"15","author":"AA Abouelkhair","year":"2026","unstructured":"Abouelkhair AA, Abutaleb NS, Seleem MN. Ionomycin Exhibits Potent and Selective Bactericidal Activity Against Clostridioides difficile Through Calcium-Dependent Membrane Disruption. MicrobiologyOpen. 2026;15(2):e70269.","journal-title":"MicrobiologyOpen"},{"issue":"2","key":"842_CR54","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis J, et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010;54(2):602\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"842_CR55","doi-asserted-by":"publisher","first-page":"e2304110120","DOI":"10.1073\/pnas.2304110120","volume":"120","author":"J Janardhanan","year":"2023","unstructured":"Janardhanan J, et al. A dual-action antibiotic that kills Clostridioides difficile vegetative cells and inhibits spore germination. Proc Natl Acad Sci U S A. 2023;120(20):e2304110120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"842_CR56","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1128\/aac.00355-23","volume":"67","author":"M Yong","year":"2023","unstructured":"Yong M, et al. Membrane Potential-Dependent Uptake of Cationic Oligoimidazolium Mediates Bacterial DNA Damage and Death. Antimicrob Agents Chemother. 2023;67(5):e00355\u201323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"842_CR57","doi-asserted-by":"publisher","first-page":"1788898","DOI":"10.1080\/19490976.2020.1795388","volume":"12","author":"MA Engevik","year":"2020","unstructured":"Engevik MA, et al. Reuterin disrupts Clostridioides difficile metabolism and pathogenicity through reactive oxygen species generation. Gut Microbes. 2020;12(1):1788898.","journal-title":"Gut Microbes"},{"key":"842_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12040818","author":"E Caballano-Infantes","year":"2023","unstructured":"Caballano-Infantes E, et al. Membrane vesicles of toxigenic Clostridioides difficile affect the metabolism of liver HepG2 cells. Antioxidants (Basel).2023 Mar 27;12(4):818. https:\/\/doi.org\/10.3390\/antiox12040818","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"842_CR59","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2008.09.002","volume":"135","author":"X Chen","year":"2008","unstructured":"Chen X, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984\u201392.","journal-title":"Gastroenterology"},{"issue":"7937","key":"842_CR60","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41586-022-05438-x","volume":"611","author":"AB Smith","year":"2022","unstructured":"Smith AB, et al. Enterococci enhance Clostridioides difficile pathogenesis. Nature. 2022;611(7937):780\u20136.","journal-title":"Nature"},{"issue":"2","key":"842_CR61","first-page":"409","volume":"75","author":"ML Hutton","year":"2019","unstructured":"Hutton ML, et al. Repurposing auranofin as a Clostridioides difficile therapeutic. J Antimicrob Chemother. 2019;75(2):409\u201317.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"842_CR62","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.taap.2011.02.020","volume":"252","author":"A Ihsan","year":"2011","unstructured":"Ihsan A, et al. Long-term mequindox treatment induced endocrine and reproductive toxicity via oxidative stress in male Wistar rats. Toxicol Appl Pharmacol. 2011;252(3):281\u20138.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"842_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14740\/gr1371","volume":"14","author":"D Solanki","year":"2021","unstructured":"Solanki D, et al. Clostridium difficile Infection Hospitalizations in the United States: Insights From the 2017 National Inpatient Sample. Gastroenterol Res. 2021;14(2):87\u201395.","journal-title":"Gastroenterol Res"},{"issue":"3","key":"842_CR64","doi-asserted-by":"publisher","first-page":"e01222","DOI":"10.1128\/aac.01222-23","volume":"68","author":"C Dureja","year":"2024","unstructured":"Dureja C, et al. In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrob Agents Chemother. 2024;68(3):e01222\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"842_CR65","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00033-18","author":"K Rao","year":"2018","unstructured":"Rao K, Higgins PDR, Young VB. An observational cohort study of Clostridium difficile ribotype 027 and recurrent infection. mSphere. 2018 May 23;3(3):e00033-18.. https:\/\/doi.org\/10.1128\/mSphere.00033-18","journal-title":"mSphere"},{"issue":"1","key":"842_CR66","doi-asserted-by":"publisher","first-page":"33642","DOI":"10.1038\/srep33642","volume":"6","author":"M Gooyit","year":"2016","unstructured":"Gooyit M, Janda KD. Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile. Sci Rep. 2016;6(1):33642.","journal-title":"Sci Rep"},{"issue":"1","key":"842_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3201\/eid0901.020172","volume":"9","author":"CW Stratton","year":"2003","unstructured":"Stratton CW. Dead bugs don\u2019t mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis. 2003;9(1):10\u20136.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"842_CR68","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jac\/dkv006","volume":"70","author":"D Corbett","year":"2015","unstructured":"Corbett D, et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother. 2015;70(6):1751\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"842_CR69","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1128\/AAC.05360-11","volume":"56","author":"MN Martinez","year":"2012","unstructured":"Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795\u2013805.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"842_CR70","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","volume":"38","author":"NJ Onufrak","year":"2016","unstructured":"Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther. 2016;38(9):1930\u201347.","journal-title":"Clin Ther"},{"issue":"6","key":"842_CR71","doi-asserted-by":"publisher","first-page":"e0130385","DOI":"10.1371\/journal.pone.0130385","volume":"10","author":"H Mohammad","year":"2015","unstructured":"Mohammad H, et al. Antibacterial Characterization of Novel Synthetic Thiazole Compounds against Methicillin-Resistant Staphylococcus pseudintermedius. PLoS ONE. 2015;10(6):e0130385.","journal-title":"PLoS ONE"},{"issue":"3","key":"842_CR72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/dks450","volume":"68","author":"F Babakhani","year":"2013","unstructured":"Babakhani F, et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother. 2013;68(3):515\u201322.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"842_CR73","doi-asserted-by":"publisher","first-page":"15735","DOI":"10.1038\/s41598-018-33954-2","volume":"8","author":"N Roshan","year":"2018","unstructured":"Roshan N, et al. Effect of natural products on the production and activity of Clostridium difficile toxins in vitro. Sci Rep. 2018;8(1):15735.","journal-title":"Sci Rep"},{"issue":"12","key":"842_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/annotation\/f9017013-88c8-44db-818b-08b9322f3814","volume":"8","author":"NM Chumbler","year":"2012","unstructured":"Chumbler NM, et al. Correction: Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog. 2012;8(12):10.1371\/annotation\/f9017013-88c8-44db-818b-08b9322f3814.","journal-title":"PLoS Pathog"},{"issue":"10","key":"842_CR75","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/infdis\/jit068","volume":"207","author":"A Howerton","year":"2013","unstructured":"Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infection. J Infect Dis. 2013;207(10):1498\u2013504.","journal-title":"J Infect Dis"},{"issue":"1","key":"842_CR76","doi-asserted-by":"publisher","first-page":"e000038","DOI":"10.1136\/bmjgast-2015-000038","volume":"2","author":"LT Erikstrup","year":"2015","unstructured":"Erikstrup LT, et al. Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. BMJ Open Gastroenterol. 2015;2(1):e000038.","journal-title":"BMJ Open Gastroenterol"},{"issue":"7","key":"842_CR77","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/0011-393X(95)85137-2","volume":"56","author":"CH Asrani","year":"1995","unstructured":"Asrani CH, et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a primary care physician research group study. Curr therapeutic Res. 1995;56(7):678\u201383.","journal-title":"Curr therapeutic Res"},{"issue":"6","key":"842_CR78","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrmicro2333","volume":"8","author":"MA Kohanski","year":"2010","unstructured":"Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423\u201335.","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl(Suppl)","key":"842_CR79","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1194\/jlr.R800046-JLR200","volume":"50","author":"YM Zhang","year":"2009","unstructured":"Zhang YM, Rock CO. Transcriptional regulation in bacterial membrane lipid synthesis. J Lipid Res. 50 Suppl(Suppl), S115\u2013S119. https:\/\/doi.org\/10.1194\/jlr.R800046-JLR200.","journal-title":"J Lipid Res"},{"issue":"5","key":"842_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1128\/AAC.3.5.549","volume":"3","author":"I Goldberg","year":"1973","unstructured":"Goldberg I, Walker JR, Bloch K. Inhibition of lipid synthesis in Escherichia coli cells by the antibiotic cerulenin. Antimicrob Agents Chemother. 1973;3(5):549\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"842_CR81","doi-asserted-by":"publisher","first-page":"eadd9280","DOI":"10.1126\/sciadv.add9280","volume":"9","author":"RAG da Silva","year":"2023","unstructured":"da Silva RAG, et al. Mitoxantrone targets both host and bacteria to overcome vancomycin resistance in Enterococcus faecalis. Sci Adv. 2023;9(8):eadd9280.","journal-title":"Sci Adv"},{"issue":"5","key":"842_CR82","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.celrep.2015.09.059","volume":"13","author":"P Belenky","year":"2015","unstructured":"Belenky P, et al. Bactericidal Antibiotics Induce Toxic Metabolic Perturbations that Lead to Cellular Damage. Cell Rep. 2015;13(5):968\u201380.","journal-title":"Cell Rep"},{"issue":"10","key":"842_CR83","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1128\/AEM.00189-08","volume":"74","author":"TB Stanton","year":"2008","unstructured":"Stanton TB, et al. Collateral Effects of Antibiotics: Carbadox and Metronidazole Induce VSH-1 and Facilitate Gene Transfer among Brachyspira hyodysenteriae Strains. Appl Environ Microbiol. 2008;74(10):2950\u20136.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"842_CR84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mrgentox.2011.10.012","volume":"741","author":"J Liu","year":"2012","unstructured":"Liu J, et al. Mequindox induced cellular DNA damage via generation of reactive oxygen species. Mutat Research\/Genetic Toxicol Environ Mutagen. 2012;741(1):70\u20135.","journal-title":"Mutat Research\/Genetic Toxicol Environ Mutagen"},{"issue":"18","key":"842_CR85","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1128\/JB.182.18.5091-5096.2000","volume":"182","author":"G Sisson","year":"2000","unstructured":"Sisson G, et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. J Bacteriol. 2000;182(18):5091\u20136.","journal-title":"J Bacteriol"},{"issue":"5","key":"842_CR86","doi-asserted-by":"publisher","first-page":"e0156322","DOI":"10.1128\/aac.01563-22","volume":"67","author":"CS Mason","year":"2023","unstructured":"Mason CS, et al. The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023;67(5):e0156322.","journal-title":"Antimicrob Agents Chemother"},{"key":"842_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101126","author":"TA Eubank","year":"2025","unstructured":"Eubank TA, et al. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025. https:\/\/doi.org\/10.1016\/j.lanmic.2025.101126.","journal-title":"Lancet Microbe"},{"issue":"Suppl 2","key":"842_CR88","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1093\/cid\/cis356","volume":"55","author":"DW Eyre","year":"2012","unstructured":"Eyre DW, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55(Suppl 2):S77\u201387.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"842_CR89","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/cid\/cis430","volume":"55","author":"LA Petrella","year":"2012","unstructured":"Petrella LA, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55(3):351\u20137.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"842_CR90","volume":"61","author":"U Nayak Seema","year":"2017","unstructured":"Nayak Seema U, et al. Safety, tolerability, systemic exposure, and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile, in a phase 1 study. Antimicrob Agents Chemother. 2017;61(8):10.1128\/aac.02760-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"842_CR91","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/19440049.2018.1461255","volume":"35","author":"X Miao","year":"2018","unstructured":"Miao X, et al. Determination of olaquindox, carbadox and cyadox in animal feeds by ultra-performance liquid chromatography tandem mass spectrometry. Food Addit Contaminants: Part A. 2018;35(7):1257\u201365.","journal-title":"Food Addit Contaminants: Part A"},{"issue":"1","key":"842_CR92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ilar\/ilv006","volume":"56","author":"M Wang","year":"2015","unstructured":"Wang M, Donovan SM. Human microbiota-associated swine: current progress and future opportunities. Ilar j. 2015;56(1):63\u201373.","journal-title":"Ilar j"},{"issue":"2","key":"842_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S0954422413000152","volume":"26","author":"SN Heinritz","year":"2013","unstructured":"Heinritz SN, Mosenthin R, Weiss E. Use of pigs as a potential model for research into dietary modulation of the human gut microbiota. Nutr Res Rev. 2013;26(2):191\u2013209.","journal-title":"Nutr Res Rev"},{"key":"842_CR94","doi-asserted-by":"publisher","unstructured":"Abouelkhair AA, Abutaleb NS, Stolz BJ, Seleem MN.0.Repurposing azole antifungals as rapid bactericidal, membrane-disruptive therapeutics against Clostridioides difficile. Microbiol Spectr0:e02900-25. https:\/\/doi.org\/10.1128\/spectrum.02900-25","DOI":"10.1128\/spectrum.02900-25"}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-026-00842-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-026-00842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-026-00842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:01:41Z","timestamp":1784134901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13099-026-00842-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1186\/s13099-026-00842-4","relation":{},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal care and experimental procedures were reviewed and approved by Virginia Polytechnic Institute and State University ((IACUC 23\u2013175)) and conducted in full compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}